SCHEDULE: Trails Edge Discloses 6% Stake in Camp4 Therapeutics

Trails Edge Capital Partners, LP, along with affiliated entities, has reported beneficial ownership of approximately 6% of Camp4 Therapeutics Corp.'s common stock as of August 3, 2026.

Summary

• Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai (collectively, the 'Filers') have filed a Schedule 13G.
• As of August 3, 2026, the Filers beneficially own 3,790,636 shares of Camp4 Therapeutics Corp. common stock.
• This represents approximately 6% of the Issuer's outstanding shares.
• The shares are held directly by Trails Edge Biotechnology Master Fund, LP.
• Trails Edge Capital Partners, LP is the investment manager for Trails Edge Biotechnology Master Fund, LP.
• Ortav Yehudai is the Chief Investment Officer of Trails Edge Capital Partners, LP and exercises voting and investment discretion.
• The filing certifies that these securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily indicating a significant but passive investment stake without immediate implications for control or strategy changes.

Positives

• Significant passive investment stake reported by a notable investment entity.
• Ownership percentage (6%) indicates a substantial position in the company.
• The filing confirms the investment is not intended to influence or change control, suggesting a focus on investment returns rather than activism.

Negatives

• No specific operational or financial performance data is disclosed in this filing, as it is a Schedule 13G.
• The filing does not provide details on the investment strategy or rationale behind acquiring the stake.

Risks

• Potential for future changes in investment strategy by Trails Edge, which could impact share price.
• Market perception of a large passive stake could influence trading dynamics.
• Dependence on the Issuer's future performance for investment returns.

Future Outlook

This filing is a Schedule 13G, which reports passive ownership stakes. It does not contain forward-looking statements or guidance from Camp4 Therapeutics Corp. itself. The future outlook for the investment depends on the performance of Camp4 Therapeutics Corp.

Management Comments

• "Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a 'Filer' and collectively as the 'Filers'."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect..."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that the biotechnology sector is characterized by significant investment activity, with specialized funds like Trails Edge Biotechnology often taking substantial stakes. This filing indicates a notable investment in Camp4 Therapeutics, a company operating within this dynamic industry.

Stakeholder Impact

• Shareholders: May view the significant stake as a positive signal of institutional interest, but the passive nature of the filing limits immediate impact on share price.
• Management of Camp4 Therapeutics Corp.: Will be aware of a substantial passive investor, which could influence future strategic decisions or investor relations efforts.
• Potential Investors: May use this filing as an indicator of institutional confidence in Camp4 Therapeutics Corp.

Next Steps

• Continued monitoring of Camp4 Therapeutics Corp.'s performance and any subsequent filings by Trails Edge.
• Potential for Trails Edge to increase or decrease its stake in the future, which would trigger new filings.

Key Dates

Keywords

Camp4 Therapeutics, Trails Edge Capital Partners, Schedule 13G, Beneficial Ownership, Investment Stake, Common Stock, Biotechnology